WCN26-4900 Clinical Outcomes and Renal Recovery after Glucarpidase Rescue in High-Dose Methotrexate–Induced Acute Kidney Injury: A Systematic Review

Read full text Summarise with VIRAT
Authors: Andree Kurniawan, Angeline Tancherla, Jeremia Siregar, Vidhia Umami, Dina Nilasari, Margaret Merlyn Tjiang, Donnie Lumban Gaol, Fernando Dharmaraja
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

High-dose methotrexate (HD-MTX) is a cornerstone in the treatment of hematologic malignancies and certain solid tumors, including osteosarcoma and germ cell tumors. However, HD-MTX can cause acute kidney injury (AKI) and delayed MTX clearance, leading to severe systemic toxicity. Glucarpidase (carboxypeptidase G2) is an enzymatic rescue therapy that rapidly hydrolyzes MTX into inactive metabolites. This systematic review aimed to evaluate the impact of glucarpidase on renal recovery and clinical outcomes in patients with HD-MTX–induced AKI or delayed MTX elimination.

Fields of Study & Subjects

Acute Kidney Injury Research Chemotherapy-induced organ toxicity mitigation Methemoglobinemia and Tumor Lysis Syndrome

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105686–105686
Publication date
25 March 2026
Language
EN